Location of the Meso-pancreatoduodenum as a Regional Lymphatic Basin for Pancreatic Head Carcinoma

13301甲第4500号博士（医学）金沢大学博士論文本文Full 以下に掲載予定：Oncology Letters. spandidos Publications. 共著者：HIROFUMI TERAKAWA, HIROHISA KITAGAWA, ISAMU MAKINO, HIRONORI HAYASHI, KATSUNOBU OYAMA, HISATOSHI NAKAGAWARA, TOMOHARU MIYASHITA, HIDEHIRO TAJIMA, HIROYUKI TAKAMURA, SACHIO FUSHIDA, NORIYUKI OZAKI, TETSUO OHT

Location of the Meso-pancreatoduodenum as a Regional Lymphatic Basin for Pancreatic Head Carcinoma

13301甲第4500号博士（医学）金沢大学博士論文要旨Abstract 以下に掲載予定：Oncology Letters. spandidos Publications. 共著者：HIROFUMI TERAKAWA, HIROHISA KITAGAWA, ISAMU MAKINO, HIRONORI HAYASHI, KATSUNOBU OYAMA, HISATOSHI NAKAGAWARA, TOMOHARU MIYASHITA, HIDEHIRO TAJIMA, HIROYUKI TAKAMURA, SACHIO FUSHIDA, NORIYUKI OZAKI, TETSUO OHT

Clinical and radiological feature of lymphoepithelial cyst of the pancreas

A lymphoepithelial cyst (LEC) of the pancreas is a rare benign lesion. Because patients with LEC of the pancreas have a good prognosis, it is important that these lesions are accurately differentiated from other more aggressive pancreatic neoplasms for an appropriate treatment strategy. Previous studies have reported that a definitive diagnosis of LEC often cannot be obtained based solely on the findings of preoperative imaging (e.g. , Computed tomography or Magnetic resonance imaging). In this study, we reviewed four cases of pancreatic LECs to investigate the feature of LECs. We reviewed these cases with regard to symptoms, imaging findings, surgical procedures, and other clinical factors. We found that LEC was associated with unique characteristics on imaging findings. A preoperative diagnosis of LEC may be possible by comprehensively evaluating its clinical and imaging findings

Hepatocellular carcinoma and type 2 diabetes mellitus: two cases highlighting changes in tumor glycogen content

This article reports two patients with hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM), who showed marked changes in hepatocellular glycogen content. Periodic acid-Schiff (PAS)-positive and diastase-PAS-negative (glycogen-storing) hepatocytes were detected in both background liver parenchyma and in HCC tissues. In HCC tissues, the number of glycogen-storing cells resembling hepatocytes was considerably reduced and unevenly distributed as compared with hepatocytes in background liver. To be known, changes in hepatocellular glycogen content in T2DM patients have not been previously described. It is hypothesized that the reduction in glycogen content in both patients was likely associated with the emergence of Warburg type of glycolysis

A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic

Tumor cells adapt to their high metabolic state by increasing energy production. To this end, current efforts in molecular cancer therapeutics have been focused on signaling pathways that modulate cellular metabolism. However, targeting such signaling pathways is challenging due to heterogeneity of tumors and recurrent oncogenic mutations. A critical need remains to develop antitumor drugs that target tumor specific pathways. Here, we discuss an energy metabolic pathway that is preferentially activated in several cancers as a potential target for molecular cancer therapy. In vitro studies have revealed that many cancer cells synthesize guanosine triphosphate (GTP), via the de novo purine nucleotide synthesis pathway by upregulating the rate limiting enzyme of this pathway, inosine monophosphate dehydrogenase (IMPDH). Non-proliferating cells use an alternative purine nucleotide synthesis pathway, the salvage pathway, to synthesize GTP. These observations pose IMPDH as a potential target to suppress tumor cell growth. The IMPDH inhibitor, mycophenolate mofetil (MMF), is an FDA-approved immunosuppressive drug. Accumulating evidence shows that, in addition to its immunosuppressive effects, MMF also has antitumor effects via IMPDH inhibition in vitro and in vivo. Here, we review the literature on IMPDH as related to tumorigenesis and the use of MMF as a potential antitumor drug